Metamizole Impact on Anti-Xa Levels in Oncology Patients on DOACs

This study focuses on understanding how a pain reliever called Metamizole (Optalgin®) affects the levels of a specific type of blood thinner, known as Direct Oral Anticoagulants (DOACs), in cancer patients. The goal is to see if Metamizole alters the effectiveness of DOACs. This research is important because many cancer patients need pain relief and also require blood thinners, so it's crucial to understand how these medications interact to ensure the best and safest care. During the study, participants receive both their regular DOAC medication and Metamizole at different times. The study measures the levels of DOACs in the blood at five different points, both when participants are taking Metamizole and when they are not. The main outcome being evaluated is the change in DOAC levels during these periods. This helps to determine if and how Metamizole impacts the effectiveness of DOACs.